SynthesisFrontiers in aging neuroscience2026
Sphingolipids associated research in Alzheimer's disease: an explored trends analysis.
Synthesis in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment. Numerous studies have indicated that dysregulation of sphingolipid metabolism is closely associated with the core pathology of AD and acts as a crucial driving factor. This study aims to employ bibliometric methods to comprehensively summarize the relevant research on sphingolipids in AD, identify research hotspots and emerging trends, and thereby provide objective data to guide future research directions. Methods: Publications were retrieved from the Web of Science and Scopus databases. Visual analyses were performed using CiteSpace, VOSviewer, and Bibliometrix. Results: A total of 623 publications related to sphingolipids and AD were included. The United States and China were the leading contributors in this field. Johns Hopkins University was the most prolific institution. Conclusion: Research on sphingolipids in AD exhibits an overall fluctuating upward trend. Extensive collaboration among researchers from various institutions has facilitated advancements in this field. Sphingolipid metabolism represents a key focus in AD research, with ceramides and sphingomyelins identified as critical molecules. Lipidomics, metabolomics, and microglia are likely to represent future research frontiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.